Hamilton, E. P., Laurentiis, M. D., Jhaveri, K. L., Hu, X., Ladoire, S., Patsouris, A., Zamagni, C., Cui, J., Cazzaniga, M., Çil, T., Jerzak, K. J., Fuentes, C. S., Yoshinami, T., Rodriguez-Lescure, A., Valota, O., Lu, D. R., Martignoni, M., Parameswaran, J., Zhi, X., Campone, M. (2025). Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.17_suppl.lba1000